Gastroenterology

---

Eur Rev Med Pharmacol Sci 2005; 9 (5): 299-304

The treatment of NAFLD

M. Trappoliere, C. Tuccillo, A. Federico, A. Di Leva, M. Niosi, C. D’Alessio, R. Capasso, F. Coppola, M. D’Auria, C. Loguercio

Eur Rev Med Pharmacol Sci 2005; 9 (5): 295-297

Donor liver steatosis and graft selection for liver transplantation: a short review

M. Angelico

Eur Rev Med Pharmacol Sci 2005; 9 (5): 291-293

Steatosis and hepatocellular carcinoma risk

A. Smedile, E. Bugianesi

Eur Rev Med Pharmacol Sci 2005; 9 (5): 285-290

Steatosis and portal hypertension

C. Puoti, L. Bellis

Eur Rev Med Pharmacol Sci 2005; 9 (5): 279-284

Adipokines and liver fibrosis

F. Marra1,2, S. Aleffi1, C. Bertolani1, I. Petrai1, F. Vizzutti1

Eur Rev Med Pharmacol Sci 2005; 9 (5): 273-277

The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis

L. Miele, A. Forgione, A.P. Hernandez, M.L. Gabrieli, V. Vero, P. Di Rocco, A.V. Greco, G. Gasbarrini, A. Gasbarrini, A. Grieco

Eur Rev Med Pharmacol Sci 2005; 9 (5): 269-271

Hepatic steatosis and vascular disease

A. Santoliquido, C. Di Campli*, L. Miele*, M.L. Gabrieli, A. Forgione*, M.A. Zocco*, A. Lupascu*, A. Di Giorgio*, R. Flore, P. Pola, G. Gasbarrini, A. Gasbarrini, P. Tondi, A. Grieco*

Eur Rev Med Pharmacol Sci 2005; 9 (5): 265-268

Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH)

E. Capristo, L. Miele, A. Forgione, V. Vero, S. Farnetti, G. Mingrone, A.V. Greco, G. Gasbarrini, A. Grieco

Eur Rev Med Pharmacol Sci 2005; 9 (5): 261-263

Fatty liver and drugs

A. Grieco, A. Forgione, L. Miele, V. Vero, A.V. Greco, A. Gasbarrini, G. Gasbarrini

Eur Rev Med Pharmacol Sci 2005; 9 (5): 253-259

Nonalcoholic fatty liver disease: defining a common problem

G. Gasbarrini, V. Vero, L. Miele, A. Forgione, A.P. Hernandez, A.V. Greco, A. Gasbarrini, A. Grieco

Eur Rev Med Pharmacol Sci 2005; 9 (5): 251-252

Attraction and growing interest for the fatty liver by the scientific associations

A. Benedetti

Eur Rev Med Pharmacol Sci 2005; 9 (5): 249-250

NAFLD and NASH: behind the fat, there’s something more (Editorial)

A. Grieco, L. Miele, G. Gasbarrini

Eur Rev Med Pharmacol Sci 2005; 9 (4): 223-225

Giant mesenteric fibromatosis

M. Batori, E. Chatelou, G. Mariotta, G. Sportelli, A. Straniero, G. Casella, M.C. Casella

Eur Rev Med Pharmacol Sci 2005; 9 (4): 217-222

Treatment of small intestine bacterial overgrowth

M. Di Stefano, E. Miceli, A. Missanelli, G.R. Corazza

Eur Rev Med Pharmacol Sci 2005; 9 (3): 151-160

Role of gastroesophageal reflux disease in asthmatic patients

S.-P. Jiang, L.-W. Huang

Eur Rev Med Pharmacol Sci 2005; 9 (1): 29-35

Electrogastrography

Z. Rossi, G. Forlini, P. Fenderico, R. Cipolla, S. Nasoni

Eur Rev Med Pharmacol Sci 2005; 9 (1): 23-28

The role of gastric accommodation in the pathophysiology of functional dyspepsia

M. Di Stefano, E. Miceli, S. Mazzocchi, P. Tana, G.R. Corazza

Eur Rev Med Pharmacol Sci 2005; 9 (1): 15-21

Gastric emptying and intragastric balloon in obese patients

P. Bonazzi, M.D. Petrelli*, I. Lorenzini, E. Peruzzi, A. Nicolai*, R. Galeazzi

Eur Rev Med Pharmacol Sci 2005; 9 (1): 9-13

13C-octanoic acid breath test in functional and organic disease: critical review of literature

P. Usai Satta, M. Scarpa, F. Oppia, F. Loriga

Eur Rev Med Pharmacol Sci 2005; 9 (1): 3-8

13C-octanoic acid breath test for measuring gastric emptying of solids

F. Perri, M.R. Pastore*, V. Annese